Episode 89: A Day in the Life of an Editor-in-Chief With Nora Disis

Episode 89: A Day in the Life of an Editor-in-Chief With Nora Disis

Chadi invites Mary L (Nora) Disis, MD, editor-in-chief of Jama Oncology, to learn the ins-and-outs of what it takes to be the lead editor of a highly prestigious oncology journal. She shares what went into her decision to accept the editor-in-chief position and help launch the journal in 2015, what goes into her thought process for rejecting submissions and handling disgruntled authors, management and pain points of “content” and “statistical” peer-reviewers, thoughts on the oversaturation of poorly written COVID-19 papers published in high-impact journals, and plans for the future direction of the journal.

Related Resources

This podcast was produced by the Journal of Clinical Pathways.

Subscribe to Healthcare Unfiltered

Other Episodes You May Enjoy...

Episode 223: From Lab to Statup: Dr. Simrit Parmar on Launching Cellenkos

Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous

Read More

Episode 222: Language Matters: A Patient Perspective

Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those

Read More

Episode 221: Major Progress in Adjuvant Renal Cell Carcinoma

Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease

Read More